genmab
announces
data
presented
ash
annual
meeting
media
release
copenhagen
denmark
november
abstracts
genmab
owned
partnered
programs
scheduled
presentation
ash
data
ongoing
phase
ii
epcoritamab
trial
accepted
oral
presentation
daratumumab
featured
five
oral
presentations
total
accepted
abstracts
including
iss
investigator
sponsored
studies
market
access
abstracts
genmab
host
virtual
ash
data
review
meeting
december
genmab
nasdaq
gmab
announced
today
abstracts
related
genmab
owned
partnered
programs
accepted
presentation
american
society
hematology
ash
annual
meeting
taking
place
virtually
december
abstracts
accepted
presentation
include
data
ongoing
phase
ii
trial
epcoritamab
lymphomas
presented
oral
session
conference
accepted
abstracts
also
include
data
genmab
next
generation
antibody
updates
multiple
daratumumab
clinical
trials
addition
data
teclistamab
talquetamab
two
janssen
bispecific
antibodies
created
genmab
duobody
technology
platform
accepted
oral
presentations
conference
abstracts
available
ash
website
details
regarding
key
abstracts
presented
included
another
strong
year
genmab
proprietary
pipeline
progressing
rapidly
excited
sharing
additional
data
epcoritamab
program
oral
presentation
prestigious
ash
conference
well
data
clinical
program
said
jan
van
de
winkel
chief
executive
officer
genmab
also
pleased
see
significant
number
daratumumab
abstracts
accepted
presentation
confirms
confidence
broad
potential
late
breaking
abstracts
yet
available
december
pm
est
pm
cet
pm
gmt
genmab
hold
virtual
ash
data
review
present
key
priorities
event
webcast
live
following
link
https
mmc
p
details
including
webcast
link
also
found
genmab
website
meeting
official
program
ash
annual
meeting
genmab
abstracts
subcutaneous
epcoritamab
induces
complete
responses
encouraging
safety
profile
across
relapsed
refractory
lymphoma
subtypes
including
patients
prior
therapy
updated
oral
presentation
sunday
december
pst
novel
model
leveraging
preclinical
clinical
data
inform
recommended
phase
dose
selection
epcoritamab
duobody
poster
presentation
monday
december
pm
pst
preclinical
activity
b
cell
lymphoma
acute
myeloid
leukemia
xenograft
poster
presentation
sunday
december
pm
pst
key
abstracts
sponsored
janssen
biotech
include
apollo
phase
randomized
study
subcutaneous
daratumumab
plus
pomalidomide
dexamethasone
versus
pomalidomide
dexamethasone
pd
alone
patients
pts
relapsed
refractory
multiple
myeloma
rrmm
oral
presentation
sunday
december
pm
pst
daratumumab
dara
plus
lenalidomide
bortezomib
dexamethasone
rvd
patients
newly
diagnosed
multiple
myeloma
ndmm
updated
analysis
griffin
maintenance
therapy
oral
presentation
monday
december
pst
reduction
absolute
involved
free
light
chain
difference
involved
uninvolved
free
light
chain
associated
prolonged
major
organ
deterioration
survival
patients
newly
diagnosed
al
amyloidosis
receiving
bortezomib
cyclophosphamide
dexamethasone
without
daratumumab
results
andromeda
oral
presentation
monday
december
pst
updated
analysis
daratumumab
plus
lenalidomide
dexamethasone
versus
lenalidomide
dexamethasone
rd
patients
newly
diagnosed
multiple
myeloma
ndmm
phase
maia
study
poster
presentation
sunday
december
pm
pst
updated
phase
results
teclistamab
maturation
antigen
bcma
x
bispecific
antibody
relapsed
refractory
multiple
myeloma
rrmm
oral
presentation
saturday
december
pm
pst
phase
study
talquetamab
g
receptor
family
c
group
member
x
bispecific
antibody
patients
relapsed
refractory
multiple
myeloma
rrmm
oral
presentation
saturday
december
pm
pst
genmab
genmab
publicly
traded
international
biotechnology
company
specializing
creation
development
differentiated
antibody
therapeutics
treatment
cancer
founded
company
creator
following
approved
antibodies
daratumumab
agreement
janssen
biotech
treatment
certain
multiple
myeloma
indications
territories
including
europe
japan
subcutaneous
ofatumumab
agreement
novartis
ag
treatment
adults
relapsing
forms
multiple
sclerosis
teprotumumab
agreement
roche
granting
sublicense
horizon
therapeutics
plc
treatment
thyroid
eye
disease
subcutaneous
formulation
daratumumab
known
darzalex
daratumumab
approved
europe
treatment
adult
patients
certain
multiple
myeloma
indications
first
approved
genmab
created
therapy
ofatumumab
agreement
novartis
ag
approved
treatment
certain
chronic
lymphocytic
leukemia
indications
available
japan
also
available
territories
via
compassionate
use
oncology
access
programs
daratumumab
clinical
development
janssen
treatment
additional
multiple
myeloma
indications
blood
cancers
amyloidosis
genmab
also
broad
clinical
product
pipeline
genmab
technology
base
consists
validated
proprietary
next
generation
antibody
technologies
platform
generation
bispecific
antibodies
platform
creates
effector
function
enhanced
antibodies
platform
combines
two
acting
hexabody
molecules
introduce
selectivity
maximizing
therapeutic
potency
platform
enhances
potential
potency
bispecific
antibodies
hexamerization
company
intends
leverage
technologies
create
opportunities
full
future
products
genmab
alliances
top
tier
pharmaceutical
biotechnology
companies
genmab
headquartered
copenhagen
denmark
sites
utrecht
netherlands
princeton
new
jersey
tokyo
japan
contact
marisol
peron
corporate
vice
president
communications
investor
relations
e
mmp
investor
relations
andrew
carlsen
senior
director
investor
relations
e
acn
media
release
contains
forward
looking
statements
words
believe
expect
anticipate
intend
plan
similar
expressions
identify
forward
looking
statements
actual
results
performance
may
differ
materially
future
results
performance
expressed
implied
statements
important
factors
could
cause
actual
results
performance
differ
materially
include
among
others
risks
associated
clinical
development
products
uncertainties
related
outcome
conduct
clinical
trials
including
unforeseen
safety
issues
uncertainties
related
product
manufacturing
lack
market
acceptance
products
inability
manage
growth
competitive
environment
relation
business
area
markets
inability
attract
retain
suitably
qualified
personnel
unenforceability
lack
protection
patents
proprietary
rights
relationships
affiliated
entities
changes
developments
technology
may
render
products
technologies
obsolete
factors
discussion
risks
please
refer
risk
management
sections
genmab
recent
financial
reports
available
risk
factors
included
genmab
recent
annual
report
form
filings
securities
exchange
commission
sec
available
genmab
undertake
obligation
update
revise
forward
looking
statements
media
release
confirm
statements
reflect
subsequent
events
circumstances
date
made
relation
actual
results
unless
required
law
genmab
subsidiaries
following
trademarks
genmab
genmab
combination
genmab
duobody
combination
duobody
hexabody
combination
hexabody
trademarks
novartis
ag
affiliates
darzalex
trademarks
janssen
pharmaceutica
nv
trademark
horizon
therapeutics
plc
media
release
cvr
lei
code
genmab
kalvebod
brygge
copenhagen
v
denmark
attachment
